Trastuzumab Deruxtecan

Antibody–drug conjugate

Also known as DS-8201

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, HR+/HER2- Metastatic Breast Cancer (label: HER2-low and HER2-ultralow metastatic breast cancer, HR-positive or HR-negative, after prior...), Breast Cancer, HER2-Positive Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
US
  • HER2-Low and HER2-Ultralow Metastatic Breast Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic Hormone receptor (HR)-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-authorized test, that has progressed on one or more endocrine therapies in the metastatic setting [see Dosage and Administration (2.1) ] . HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-authorized test, who have received a prior chemotherapy in the metastatic settin
  • HER2-Positive Locally Advanced or Metastatic Gastric Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
Product first approved 2019FDA label
EU
  • Enhertu (with pertuzumab): 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancerastrazeneca.com
  • Breast cancerHER2-positive breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.HER2-low and HER2-ultralow breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next...
    EMA
Product first approved 2021

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (23)
Breast Cancer
HER2-Positive Breast Cancer
NCT07578116 · SWOG Cancer Research Network
2027-03-09 – 2033-05-31 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
What this study did
NCT04739761 · AstraZeneca
2021-06-22 – 2027-05-26 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07828054 · Mario Negri Institute for Pharmacological Research
2026-12-20 – 2030-12-20 · Breast Cancer, Interstitial Lung Disease (ILD)
What this study did
NCT07683754 · Daiichi Sankyo
2026-11-04 – 2030-08-28 · Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
What this study did
NCT06585969 · Danish Breast Cancer Cooperative Group
2026-01-01 – 2026-01-01 · Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B, Her2 Enriched, Basal Like
What this study did
Non-Small Cell Lung Cancer
NCT05048797 · AstraZeneca
2021-10-28 – 2027-07-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07022483 · Daiichi Sankyo
2025-09-30 – 2032-03-23 · Endometrial Cancer
What this study did
NCT06764875 · AstraZeneca
2025-03-01 – 2030-12-09 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06731478 · Daiichi Sankyo
2025-02-27 – 2030-02-01 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT06467357 · AstraZeneca
2024-08-12 – 2029-05-16 · Biliary Tract Cancer
What this study did
NCT06174987 · Daiichi Sankyo
2024-01-05 – 2028-02-17 · Advanced Cancer, Metastatic Cancer
What this study did
NCT04704934 · Daiichi Sankyo
2021-05-21 – 2026-08-31 · Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2 (70)
Breast Cancer
NCT07393425 · Shanghai Jiao Tong University School of Medicine
2026-02-02 – 2032-09-30 · HER2 + Breast Cancer
What this study did
NCT07905313 · Azienda Ospedaliero-Universitaria Careggi
2027-05-15 – 2030-12-31 · Breast Cancer (Advanced/Metastatic)
What this study did
NCT05704829 · Women's Cancer Study Group GmbH
2024-02-05 – 2030-09 · HER2-positive Early Breast Cancer
What this study did
NCT07371585 · SOLTI Breast Cancer Research Group
2026-02-18 – 2030-07-01 · Breast Cancer Stage IV
What this study did
NCT07836257 · Fujian Medical University
2026-10-10 – 2029-10-30 · Breast Cancer
What this study did
NCT07151586 · UNICANCER
2026-09 – 2029-10 · Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer
What this study did
NCT06733233 · Guangzhou Women and Children's Medical Center
2025-01-01 – 2029-01-01 · Breast Cancer, Estrogen Receptor-Positive, HER2 Low Breast Cancer
What this study did
NCT05953168 · Fudan University
2023-08 – 2026-08 · Triple-Negative Breast Cancer
What this study did
NCT05744375 · Spanish Breast Cancer Research Group
2023-09-28 – 2025-07-17 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT06439693 · Dana-Farber Cancer Institute
2024-08-08 – 2033-03-30 · Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
What this study did
NCT05795101 · Filipa Lynce, MD
2023-05-04 – 2032-12-01 · Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
What this study did
NCT05900206 · Karolinska University Hospital
2023-10-26 – 2032-04-30 · Breast Cancer
What this study did
NCT07459673 · Memorial Sloan Kettering Cancer Center
2026-03-04 – 2030-03-04 · Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
What this study did
NCT06172127 · MedSIR
2024-07-22 – 2029-06 · HER2-positive Breast Cancer
What this study did
NCT06548178 · Fudan University
2024-09 – 2028-09 · HER2-positive Breast Cancer
What this study did
NCT05710666 · Cancer Trials Ireland
2023-10-26 – 2028-03-30 · HER2-positive Breast Cancer
What this study did
NCT06797622 · Fudan University
2025-02-15 – 2027-04-15 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT06088056 · Fudan University
2023-11 – 2026-07 · Breast Cancer, Brain Metastases, Radiotherapy
What this study did
NCT04539938 · Seagen, a wholly owned subsidiary of Pfizer
2020-12-01 – 2025-03-07 · HER2 Positive Breast Cancer
What this study did
NCT04752059 · Medical University of Vienna
2020-07-28 – 2023-05-01 · Breast Cancer Stage IV
What this study did
NCT04420598 · MedSIR
2020-05-25 – 2023-04-04 · Advanced Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Leptomeningeal Metastasis
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06533826 · Ana C Garrido-Castro, MD
2024-10-29 – 2038-08-01 · Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT05982678 · The Netherlands Cancer Institute
2024-05-02 – 2034-10-01 · HER2-positive Breast Cancer
What this study did
NCT07619365 · Washington University School of Medicine
2026-11-30 – 2031-11-30 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT04986579 · Dana-Farber Cancer Institute
2021-10-07 – 2030-06-01 · Metastatic Breast Cancer, Chemotherapy-induced Alopecia
What this study did
NCT07825753 · Fudan University
2026-09-10 – 2030-02-01 · Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
What this study did
NCT06832202 · Shanghai Henlius Biotech
2025-04-16 – 2029-12-01 · HER2-low Hormone Receptor Positive Breast Cancer
What this study did
NCT06750484 · Yale University
2025-06-20 – 2028-12-31 · Breast Cancer Metastatic
What this study did
NCT07368543 · Fudan University
2026-01-16 – 2028-12-01 · Metastatic Breast Cancer
What this study did
NCT07497386 · Jiangsu HengRui Medicine Co., Ltd.
2026-04-28 – 2028-12 · Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer
What this study did
NCT07203378 · University of Utah
2025-11-04 – 2028-11 · Metastatic Breast Cancer
What this study did
NCT07150208 · Fudan University
2025-10-20 – 2028-09 · Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer
What this study did
NCT07647016 · Fudan University
2026-04-01 – 2028-02-01 · Breast Cancer
What this study did
NCT06486883 · MedSIR
2025-06-30 – 2028-01 · Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma
What this study did
NCT06409390 · H. Lee Moffitt Cancer Center and Research Institute
2024-08-14 – 2027-04 · Metastatic Breast Cancer
What this study did
NCT06271837 · AstraZeneca
2024-02-22 – 2027-02-10 · Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
What this study did
NCT06048718 · MedSIR
2024-06-05 – 2026-11 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT06837792 · Yonsei University
2023-10-01 – 2026-10-01 · Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)
What this study did
Non-Small Cell Lung Cancer
NCT07936422 · Centre Leon Berard
2027-02 – 2036-02 · NSCLC (Advanced Non-small Cell Lung Cancer), Urothelial Cancer, Pan-rare Tumor With no T-DXd Approvals, Pan-frequent Tumors With no T-DXd Approvals
What this study did
NCT07662473 · Hunan Province Tumor Hospital
2026-07-29 – 2028-06-30 · NSCLC
What this study did
NCT07428044 · Memorial Sloan Kettering Cancer Center
2026-02-13 – 2027-02-13 · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB
What this study did
NCT05246514 · AstraZeneca
2022-07-13 – 2026-12-31 · HER2-mutant Non-Small Cell Lung Cancer
What this study did
NCT06250777 · Yonsei University
2024-07-11 – 2026-12 · Non Small Cell Lung Cancer
What this study did
NCT03334617 · AstraZeneca
2017-12-18 – 2026-09-11 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05408845 · NRG Oncology
2023-03-03 – 2033-07-31 · Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
What this study did
NCT07069712 · AstraZeneca
2025-07-17 – 2029-07-16 · Gastroesophageal Adenocarcinoma
What this study did
NCT06630130 · Jeeyun Lee
2025-01-22 – 2029-06-30 · Stomach Neoplasms
What this study did
NCT07691489 · Memorial Sloan Kettering Cancer Center
2026-10 – 2029-06 · Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
What this study did
Phase 1/2 (23)
Breast Cancer
NCT04538742 · AstraZeneca
2020-12-28 – 2030-01-31 · Metastatic Breast Cancer
What this study did
NCT07785856 · The Methodist Hospital Research Institute
2026-12 – 2029-12 · T-dxd Resistant HER2-Positive, HER2 Low Metastatic Breast Cancer
What this study did
NCT06324357 · Boehringer Ingelheim
2024-06-28 – 2029-01-08 · Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal Cancer
What this study did
NCT03742102 · AstraZeneca
2018-12-21 – 2027-02-26 · Triple Negative Breast Neoplasms
What this study did
HER2-Positive Breast Cancer
NCT05593094 · Hoffmann-La Roche
2020-09-03 – 2027-08-31 · Advanced Solid Tumors, HER2-positive Breast Cancer
What this study did
NCT05091528 · Silverback Therapeutics
2022-02-08 – 2022-07-07 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07198724 · Kristina A. Fanucci
2025-11-17 – 2038-06-01 · Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer, Breast Cancer, Breast Cancer Female
What this study did
NCT05868226 · QuantumLeap Healthcare Collaborative
2023-02-15 – 2031-12-30 · HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
What this study did
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT07134153 · Fudan University
2025-05-12 – 2027-06-28 · Breast Cancer
What this study did
NCT04644068 · AstraZeneca
2020-11-12 – 2027-05-28 · Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
What this study did
NCT05824975 · GI Innovation, Inc.
2023-05-30 – 2027-04-24 · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
What this study did
NCT06328387 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-01-29 – 2026-03-01 · Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07012031 · National Cancer Institute (NCI)
2026-06-17 – 2027-06-14 · Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
Other / comorbidity
NCT06771622 · FBD Biologics Limited
2025-03-13 – 2029-01-01 · Solid Cancer
What this study did
NCT07157956 · Convalife (Shanghai) Co., Ltd.
2025-09-10 – 2028-12-30 · Advanced Solid Tumor
What this study did
NCT06085755 · Jeeyun Lee
2024-09-30 – 2028-12-01 · Stomach Neoplasm
What this study did
NCT06525298 · Eisbach Bio GmbH
2024-09-09 – 2028-12 · Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency
What this study did
NCT07619521 · National Cancer Institute (NCI)
2027-06-01 – 2028-09-08 · Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
What this study did
NCT05417594 · AstraZeneca
2022-06-24 – 2028-02-07 · Advanced Solid Malignancies
What this study did
NCT06731803 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2025-03-25 – 2027-12-31 · Esophagogastric Adenocarcinoma
What this study did
NCT05894824 · Yonsei University
2024-02-05 – 2026-01-01 · Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer
What this study did
NCT07529613 · National Cancer Center Hospital East
2023-12-20 – 2025-12-31 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 1 (23)
Breast Cancer
NCT04704661 · National Cancer Institute (NCI)
2021-08-09 – 2027-03-31 · Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma
What this study did
HER2-Positive Breast Cancer
NCT07454668 · Baptist Health South Florida
2027-01 – 2030-02 · Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Cancer, Cancer Metastatic
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07553390 · M.D. Anderson Cancer Center
2026-11-05 – 2038-03-30 · Breast Cancer
What this study did
NCT05633979 · M.D. Anderson Cancer Center
2023-02-09 – 2032-12-31 · Breast Cancer
What this study did
NCT06840886 · Pheast Therapeutics
2025-03-31 – 2031-04 · Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Carcinosarcoma, Ovarian
What this study did
NCT07137416 · National Cancer Institute (NCI)
2026-10-06 – 2028-01-10 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic HER2-Low Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma, Unresectable HER2-Low Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Triple-Negative Breast Carcinoma
What this study did
NCT06331169 · Fudan University
2024-07-31 – 2027-06-30 · Breast Cancer
What this study did
NCT04556773 · AstraZeneca
2020-12-17 – 2027-06-01 · Metastatic Breast Cancer
What this study did
NCT04042701 · Daiichi Sankyo
2020-02-10 – 2027-03-31 · Breast Cancer, Non-small Cell Lung Carcinoma
What this study did
NCT03523572 · Daiichi Sankyo
2018-08-02 – 2023-09-12 · Breast Cancer, Urothelial Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04686305 · AstraZeneca
2021-03-09 – 2027-06-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT05650879 · Enliven Therapeutics
2023-03-20 – 2026-07 · HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
What this study did
Other / comorbidity
NCT05765851 · Daiichi Sankyo
2023-05-30 – 2031-02-28 · Advanced Solid Tumor
What this study did
NCT07318389 · M.D. Anderson Cancer Center
2026-04-22 – 2029-11-14 · Dynamic Tumor Resistance, Metastatic Colorectal Cancer
What this study did
NCT07015697 · Daiichi Sankyo
2025-07-17 – 2028-12-31 · Recurrent or Metastatic Solid Tumors
What this study did
NCT06244485 · Daiichi Sankyo
2024-02-22 – 2028-11-01 · Advanced Solid Tumor
What this study did
NCT07086768 · Lei Zheng
2026-01-26 – 2028-08-07 · Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT05372614 · National Cancer Institute (NCI)
2022-10-05 – 2028-07-17 · Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT05274048 · Fox Chase Cancer Center
2022-06-24 – 2028-06 · Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
What this study did
NCT06364410 · National Cancer Institute (NCI)
2025-02-03 – 2027-07-08 · Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm
What this study did
NCT05614739 · Eli Lilly and Company
2023-01-12 – 2027-06 · Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
What this study did
NCT04294628 · National Cancer Institute (NCI)
2020-09-01 – 2027-01-19 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
What this study did
NCT04585958 · National Cancer Institute (NCI)
2021-05-21 – 2026-12-31 · Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm
What this study did
Phase 4 (5)
Breast Cancer
NCT05376878 · City of Hope Medical Center
2022-12-21 – 2027-04-27 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
What this study did
NCT06245824 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-01-30 – 2026-12-01 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07195344 · Institut Claudius Regaud
2025-10-15 – 2029-10 · Locally Advanced or Metastatic Breast Cancers
What this study did
NCT07162259 · Yan Xue
2025-10-01 – 2027-12-31 · Breast Neoplasms
What this study did
NCT06429761 · AstraZeneca
2025-01-02 – 2026-10-31 · BREAST CANCER
What this study did
Early phase / not applicable (6)
HR+/HER2- Metastatic Breast Cancer
NCT07130344 · Centre Paul Strauss
2025-09 – 2030-09 · Metastatic Breast Cancer, HER 2 Low-expressing Breast Cancer
What this study did
NCT07782086 · Shuangyue Liu
2026-09-07 – 2029-12 · Breast Cancer
What this study did
NCT07281001 · Blokhin's Russian Cancer Research Center
2025-12 – 2026-05 · HER2-positive Breast Cancer, Trastuzumab Deruxtecan
What this study did
NCT05919212 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2023-02-01 – 2026-02-01 · Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT04257162 · SOLTI Breast Cancer Research Group
2019-12-13 – 2028-05 · Metastatic Cancer
What this study did
Used as active comparator (7)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT07060807 · Merck Sharp & Dohme LLC
2025-07-21 – 2033-07-14 · Breast Neoplasms
What this study did
Phase 2/3 (1)
Breast Cancer
NCT07294508 · Shanghai Henlius Biotech
2026-02-27 – 2030-12-30 · HER2 + Breast Cancer
What this study did
Phase 2 (5)
HER2-Positive Breast Cancer
NCT07416253 · Henan Cancer Hospital
2026-03 – 2030-07 · Breast Cancer
What this study did
NCT07417241 · Peking University Cancer Hospital & Institute
2026-03-31 – 2029-12-31 · Breast Cancer, HER2-positive Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07630103 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-06 – 2031-12 · Advanced Breast Cancer
What this study did
NCT07678957 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-08-31 – 2028-12 · Breast Cancer
What this study did
NCT06102824 · Guangdong Provincial People's Hospital
2024-10-01 – 2028-06-30 · HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT07543536 · Sun Yat-sen University
2026-06-08 – 2031-04-01 · Advanced/Metastatic Breast Cancer, HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
What this study did
Phase 2 (2)
Breast Cancer
NCT04553770 · Jonsson Comprehensive Cancer Center
2020-10-09 – 2026-12-31 · Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT07152782 · Fudan University
2025-09-24 – 2031-11 · Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer
What this study did
Phase 1/2 (2)
HER2-Positive Breast Cancer
NCT06253871 · Iambic Therapeutics, Inc
2024-03-25 – 2028-12 · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07701941 · Daiichi Sankyo
2026-09-17 – 2032-05-01 · Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
What this study did

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Trastuzumab Deruxtecan: this drugApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAD202
Phase 1(overall)
RadiopharmaceuticalHER2
not yet graded(overall)
No reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(101 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Trastuzumab Deruxtecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-11 · NCT06048718 · CT.gov ↗
What to watch
December 2026 (3)
Phase 2Non-Small Cell Lung CancerEnrolling by invitation
Est. primary completion 2026-12 · NCT06250777 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06331169 · CT.gov ↗
What to watch
Phase 1Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid NeoplasmRecruiting
Est. primary completion 2026-12-31 · NCT04585958 · CT.gov ↗
What to watch
2027 (43)
January 2027 (3)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01 · NCT06486883 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-01-15 · NCT06797622 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-30 · NCT07134153 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02-10 · NCT06271837 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Gastric Cancer, HER2-positive Gastric CancerRecruiting
Est. primary completion 2027-03-01 · NCT06253650 · CT.gov ↗
What to watch
Phase 2Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric …Active not recruiting
Est. primary completion 2027-03-23 · NCT04482309 · CT.gov ↗
What to watch
Phase 1Breast CancerActive not recruiting
Est. primary completion 2027-03-31 · NCT04704661 · CT.gov ↗
What to watch
April 2027 (4)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-04 · NCT06172127 · CT.gov ↗
What to watch
Phase 4Breast CancerRecruiting
Est. primary completion 2027-04-27 · NCT05376878 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05900206 · CT.gov ↗
What to watch
May 2027 (4)
Phase 2Colorectal Cancer, Resectable Colorectal CarcinomaRecruiting
Est. primary completion 2027-05 · NCT05845450 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-05-03 · NCT04784715 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-05-04 · NCT04379596 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05-28 · NCT04644068 · CT.gov ↗
What to watch
June 2027 (6)
Phase 1Gastric Cancer, Gastrointestinal Cancer, HER2 Gene MutationRecruiting
Est. primary completion 2027-06 · NCT05274048 · CT.gov ↗
What to watch
Phase 1Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05614739 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-01 · NCT06832202 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT07368543 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-14 · NCT07012031 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT04686305 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2027-07-08 · NCT06364410 · CT.gov ↗
What to watch
August 2027 (2)
Phase 1Solid Tumor, Advanced Solid Tumor, Metastatic Solid TumorRecruiting
Est. primary completion 2027-08-07 · NCT07086768 · CT.gov ↗
What to watch
Phase 1/2Breast CancerActive not recruiting
Est. primary completion 2027-08-31 · NCT05593094 · CT.gov ↗
What to watch
September 2027 (4)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-09 · NCT07150208 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
Phase 2Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis, Recurrent GlioblastomaRecruiting
Est. primary completion 2027-09-22 · NCT06058988 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-09-30 · NCT07393425 · CT.gov ↗
What to watch
October 2027 (4)
Phase 2Prostate Cancer Metastatic, Prostate Cancer, CRPCRecruiting
Est. primary completion 2027-10 · NCT06610825 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-10-01 · NCT05982678 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-10-01 · NCT05950945 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma, Rectal Cancer, Metastatic …Recruiting
Est. primary completion 2027-10-20 · NCT07407465 · CT.gov ↗
What to watch
November 2027 (3)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-11 · NCT07203378 · CT.gov ↗
What to watch
Phase 2Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2027-11-09 · NCT07069712 · CT.gov ↗
What to watch
Phase 1Dynamic Tumor Resistance, Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-11-14 · NCT07318389 · CT.gov ↗
What to watch
December 2027 (8)
Phase 1/2Stomach NeoplasmActive not recruiting
Est. primary completion 2027-12-01 · NCT06085755 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-01 · NCT05795101 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-30 · NCT07647016 · CT.gov ↗
What to watch
Phase 1/2Esophagogastric AdenocarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT06731803 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07662473 · CT.gov ↗
What to watch
Phase 2Desmoplastic Small Round Cell Tumor, Osteosarcoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Kidney Wilms Tumor …Recruiting
Est. primary completion 2027-12-31 · NCT04616560 · CT.gov ↗
What to watch
Phase 4HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07162259 · CT.gov ↗
What to watch
2028 (29)
January 2028 (4)
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT06733233 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-01 · NCT06533826 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-10 · NCT07137416 · CT.gov ↗
What to watch
February 2028 (2)
Phase 1/2Advanced Solid MalignanciesRecruiting
Est. primary completion 2028-02-07 · NCT05417594 · CT.gov ↗
What to watch
Phase 3Advanced Cancer, Metastatic CancerRecruiting
Est. primary completion 2028-02-17 · NCT06174987 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2028-03-31 · NCT05034887 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid NeoplasmRecruiting
Est. primary completion 2028-03-31 · NCT06311214 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-05-15 · NCT07905313 · CT.gov ↗
What to watch
June 2028 (5)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06 · NCT07497386 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-01 · NCT07198724 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-01 · NCT04986579 · CT.gov ↗
What to watch
Phase 3Gastric Cancer, Gastroesophageal Junction CancerRecruiting
Est. primary completion 2028-06-01 · NCT06731478 · CT.gov ↗
What to watch
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2028-06-12 · NCT06467357 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 1Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2028-07-17 · NCT05372614 · CT.gov ↗
What to watch
Phase 2Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 …Recruiting
Est. primary completion 2028-07-31 · NCT05408845 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2Advanced Solid TumorNot yet recruiting
Est. primary completion 2028-08-12 · NCT07157956 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1/2Advanced Solid Tumor, Homologous Recombination Deficiency, HRR DeficiencyRecruiting
Est. primary completion 2028-09 · NCT06525298 · CT.gov ↗
What to watch
Phase 1/2Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2028-09-08 · NCT07619521 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Stomach NeoplasmsRecruiting
Est. primary completion 2028-10-30 · NCT06630130 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-10-30 · NCT07836257 · CT.gov ↗
What to watch
November 2028 (3)
Phase 1Advanced Solid TumorActive not recruiting
Est. primary completion 2028-11-01 · NCT06244485 · CT.gov ↗
What to watch
Phase 2HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2Not yet recruiting
Est. primary completion 2028-11-01 · NCT07126561 · CT.gov ↗
What to watch
Phase 3Ovarian CancerRecruiting
Est. primary completion 2028-11-01 · NCT06819007 · CT.gov ↗
What to watch
December 2028 (4)
Phase 1/2Breast CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07785856 · CT.gov ↗
What to watch
Early phase / not applicableHR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07130344 · CT.gov ↗
What to watch
Phase 1Recurrent or Metastatic Solid TumorsRecruiting
Est. primary completion 2028-12-31 · NCT07015697 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06750484 · CT.gov ↗
What to watch
2029 (11)
January 2029 (2)
Phase 1/2Breast CancerRecruiting
Est. primary completion 2029-01-08 · NCT06324357 · CT.gov ↗
What to watch
Phase 3Endometrial CancerRecruiting
Est. primary completion 2029-01-19 · NCT06989112 · CT.gov ↗
What to watch
February 2029 (1)
Phase 1Breast CancerNot yet recruiting
Est. primary completion 2029-02 · NCT07454668 · CT.gov ↗
What to watch
April 2029 (2)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-04 · NCT06840886 · CT.gov ↗
What to watch
Phase 3HER2-positive Gastric Cancer, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2029-04-27 · NCT06764875 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2029-05-31 · NCT05765851 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the RectumNot yet recruiting
Est. primary completion 2029-06 · NCT07691489 · CT.gov ↗
What to watch
July 2029 (1)
Early phase / not applicableHR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-07 · NCT07782086 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2029-08-01 · NCT07371585 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2029-10 · NCT07151586 · CT.gov ↗
What to watch
Phase 4HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-10 · NCT07195344 · CT.gov ↗
What to watch
2030 (11)
February 2030 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2030-02-26 · NCT07022483 · CT.gov ↗
What to watch
March 2030 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-03-04 · NCT07459673 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2030-03-30 · NCT06439693 · CT.gov ↗
What to watch
April 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-04-24 · NCT06899126 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-06 · NCT05704829 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07-04 · NCT07683754 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-11-30 · NCT07619365 · CT.gov ↗
What to watch
December 2030 (3)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-12-20 · NCT07828054 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-12-30 · NCT05868226 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-12-31 · NCT05633979 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2032-05-31 · NCT07578116 · CT.gov ↗
What to watch
2033 (1)
February 2033 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2033-02 · NCT07936422 · CT.gov ↗
What to watch
2036 (1)
March 2036 (1)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2036-03-30 · NCT07553390 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 October 2026ApprovalEU approves Enhertu as adjuvant monotherapy in HER2-positive early breast cancer
EU, EC · Source ↗
14 September 2026Topline resultDESTINY-Lung04: Enhertu met its PFS primary endpoint vs pembrolizumab plus chemotherapy
AstraZeneca; Daiichi Sankyo · Source ↗
1 September 2026ApprovalEnhertu with pertuzumab approved in the EU for first-line HER2-positive metastatic breast cancer
EU, EC/EMA · Source ↗